Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Feb;77(4):515–521. doi: 10.1038/bjc.1998.84

Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

S Clasen 1, W A Schulz 1, C D Gerharz 1, M O Grimm 1, F Christoph 1, B J Schmitz-Dräger 1
PMCID: PMC2149915  PMID: 9484805

Abstract

The inhibitor of cyclin-dependent kinases WAF1/p21 has been shown to mediate cell cycle arrest by p53 and other factors. We have studied its expression in urothelial carcinoma. Immunohistochemistry of paraffin-embedded tissues revealed no detectable p21 protein in normal mucosa, whereas 8 of 17 (47%) carcinomata in situ, 41 of 62 (66%) pTa, 14 of 30 (47%) pT1 and 5 of 15 (33%) muscle-invasive tumours stained positive, usually with a heterogeneous pattern. Expression of p21 was associated with low grade tumours. In contrast, the frequency of p53 accumulation increased with grade and stage as did the frequency of staining for the proliferation marker Ki67. The level of WAF1 mRNA was determined relative to beta-actin mRNA by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 15 freshly frozen invasive tumours. In eight samples obtained from normal bladder mucosa, the values ranged from 0.93 to 2.19 arbitrary units (AU) (mean 1.54+/-0.37 AU), but varied widely from non-detectable to 16.21 AU (mean 3.02+/-4.44 AU) in the tumour specimens. In accord with the immunohistochemical findings, WAF1 mRNA expression was elevated over the range found in normal mucosa in 5 of 15 advanced tumours. In addition, RNA analysis revealed a decrease in expression in six tumours. No mutations were observed in the WAF1/p21 gene in these tumours, but two were heterozygous for the codon 31 polymorphism. These data indicate that p21 is frequently expressed in superficial, well differentiated urothelial carcinomas, but less often in muscle-invasive urothelial carcinomas, irrespective of their p53 status. The expression of p21 and its prevalence in low-stage tumours may reflect residual growth-regulatory influences potentially impeding but not necessarily inhibiting tumour development.

Full text

PDF
515

Images in this article

517Figure 1
on p.517

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barboule N., Mazars P., Baldin V., Vidal S., Jozan S., Martel P., Valette A. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer. 1995 Nov 27;63(5):611–615. doi: 10.1002/ijc.2910630502. [DOI] [PubMed] [Google Scholar]
  2. Cordon-Cardo C., Dalbagni G., Saez G. T., Oliva M. R., Zhang Z. F., Rosai J., Reuter V. E., Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer. 1994 Feb 1;56(3):347–353. doi: 10.1002/ijc.2910560309. [DOI] [PubMed] [Google Scholar]
  3. Datto M. B., Yu Y., Wang X. F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem. 1995 Dec 1;270(48):28623–28628. doi: 10.1074/jbc.270.48.28623. [DOI] [PubMed] [Google Scholar]
  4. Esrig D., Elmajian D., Groshen S., Freeman J. A., Stein J. P., Chen S. C., Nichols P. W., Skinner D. G., Jones P. A., Cote R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994 Nov 10;331(19):1259–1264. doi: 10.1056/NEJM199411103311903. [DOI] [PubMed] [Google Scholar]
  5. Gao X., Chen Y. Q., Wu N., Grignon D. J., Sakr W., Porter A. T., Honn K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene. 1995 Oct 5;11(7):1395–1398. [PubMed] [Google Scholar]
  6. Grimm M. O., Jürgens B., Schulz W. A., Decken K., Makri D., Schmitz-Dräger B. J. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res. 1995;23(5):293–300. doi: 10.1007/BF00300017. [DOI] [PubMed] [Google Scholar]
  7. Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995 Feb 17;267(5200):1018–1021. doi: 10.1126/science.7863327. [DOI] [PubMed] [Google Scholar]
  8. Kawasaki T., Tomita Y., Bilim V., Takeda M., Takahashi K., Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer. 1996 Nov 15;68(4):501–505. doi: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  9. Krüger S., Müller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol. 1995 Apr;75(4):480–484. doi: 10.1111/j.1464-410x.1995.tb07269.x. [DOI] [PubMed] [Google Scholar]
  10. LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1;11(7):847–862. doi: 10.1101/gad.11.7.847. [DOI] [PubMed] [Google Scholar]
  11. Li Y., Jenkins C. W., Nichols M. A., Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994 Aug;9(8):2261–2268. [PubMed] [Google Scholar]
  12. Lipponen P. K. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol. 1995 Feb;175(2):203–210. doi: 10.1002/path.1711750208. [DOI] [PubMed] [Google Scholar]
  13. Macleod K. F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995 Apr 15;9(8):935–944. doi: 10.1101/gad.9.8.935. [DOI] [PubMed] [Google Scholar]
  14. Malkowicz S. B., Tomaszewski J. E., Linnenbach A. J., Cangiano T. A., Maruta Y., McGarvey T. W. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene. 1996 Nov 7;13(9):1831–1837. [PubMed] [Google Scholar]
  15. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C. A., Dalla Palma P. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 1996 Mar 21;12(6):1319–1324. [PubMed] [Google Scholar]
  16. Missero C., Calautti E., Eckner R., Chin J., Tsai L. H., Livingston D. M., Dotto G. P. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5451–5455. doi: 10.1073/pnas.92.12.5451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Missero C., Di Cunto F., Kiyokawa H., Koff A., Dotto G. P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 1996 Dec 1;10(23):3065–3075. doi: 10.1101/gad.10.23.3065. [DOI] [PubMed] [Google Scholar]
  18. Orlow I., Lacombe L., Hannon G. J., Serrano M., Pellicer I., Dalbagni G., Reuter V. E., Zhang Z. F., Beach D., Cordon-Cardo C. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst. 1995 Oct 18;87(20):1524–1529. doi: 10.1093/jnci/87.20.1524. [DOI] [PubMed] [Google Scholar]
  19. Osawa Y., Hachiya M., Koeffler H. P., Suzuki G., Akashi M. IL-1 induces expression of WAF1 mRNA in human fibroblasts: mechanisms of accumulation. Biochem Biophys Res Commun. 1995 Nov 13;216(2):429–437. doi: 10.1006/bbrc.1995.2641. [DOI] [PubMed] [Google Scholar]
  20. Ozçelik H., Mousses S., Andrulis I. L. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res. 1995 Aug;1(8):907–912. [PubMed] [Google Scholar]
  21. Parker S. B., Eichele G., Zhang P., Rawls A., Sands A. T., Bradley A., Olson E. N., Harper J. W., Elledge S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science. 1995 Feb 17;267(5200):1024–1027. doi: 10.1126/science.7863329. [DOI] [PubMed] [Google Scholar]
  22. Schmitz-Dräger B. J., van Roeyen C. R., Grimm M. O., Gerharz C. D., Decken K., Schulz W. A., Bültel H., Makri D., Ebert T., Ackermann R. P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol. 1994;12(2):79–83. doi: 10.1007/BF00184241. [DOI] [PubMed] [Google Scholar]
  23. Shiohara M., el-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994 Dec 1;84(11):3781–3784. [PubMed] [Google Scholar]
  24. Uchida T., Wada C., Ishida H., Wang C., Egawa S., Yokoyama E., Kameya T., Koshiba K. p53 mutations and prognosis in bladder tumors. J Urol. 1995 Apr;153(4):1097–1104. [PubMed] [Google Scholar]
  25. Vet J. A., Bringuier P. P., Schaafsma H. E., Witjes J. A., Debruyne F. M., Schalken J. A. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest. 1995 Dec;73(6):837–843. [PubMed] [Google Scholar]
  26. Watanabe H., Fukuchi K., Takagi Y., Tomoyasu S., Tsuruoka N., Gomi K. Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta. 1995 Sep 19;1263(3):275–280. doi: 10.1016/0167-4781(95)00110-3. [DOI] [PubMed] [Google Scholar]
  27. Williamson M. P., Elder P. A., Knowles M. A. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer. 1994 Feb;9(2):108–118. doi: 10.1002/gcc.2870090206. [DOI] [PubMed] [Google Scholar]
  28. Wright C., Mellon K., Johnston P., Lane D. P., Harris A. L., Horne C. H., Neal D. E. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer. 1991 Jun;63(6):967–970. doi: 10.1038/bjc.1991.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Xu H. J., Cairns P., Hu S. X., Knowles M. A., Benedict W. F. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 1993 Mar 12;53(5):781–784. doi: 10.1002/ijc.2910530513. [DOI] [PubMed] [Google Scholar]
  30. Yang Z. Y., Perkins N. D., Ohno T., Nabel E. G., Nabel G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1995 Oct;1(10):1052–1056. doi: 10.1038/nm1095-1052. [DOI] [PubMed] [Google Scholar]
  31. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  32. el-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burrell M., Hill D. E., Healy E., Rees J. L., Hamilton S. R. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995 Jul 1;55(13):2910–2919. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES